News

Illumina Faces €432 Million Fine for Completing Grail Acquisition without Approval

1 Mins read

Gene-sequencing company Illumina (ticker: ILMN) has been fined €432 million ($476 million) by the European Commission for finalizing its acquisition of cancer test developer Grail before obtaining the necessary approvals. The fine comes after the commission raised concerns about competition and launched an investigation into the acquisition in July 2021.

The European Commission stated that Illumina and Grail announced their merger just a month after the investigation began, disregarding the commission’s rules that prohibit companies from merging before clearance. Margrethe Vestager, the EU’s antitrust commissioner, emphasized the severity of this breach: “Today’s decision to fine both companies, for a total amount of €432 million, shows that this is a very serious infringement.”

An Illumina spokesperson expressed the company’s intention to appeal the decision. They believe that the fine, although expected and accounted for over the past year, is unlawful, inappropriate, and disproportionate. The spokesperson justified the early closure of the transaction by stating that there were no obstacles in the United States, and the deal timeframe would have expired before the European Commission reached a decision.

During premarket trading on Wednesday, shares of Illumina were down 0.2% to $184.37. So far this year, the stock has seen an 8.6% decline.

Related posts
News

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…
News

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…
News

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *